Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Huntington’s Disease Treatment Market: By Treatment Type, By Drug Type, By Distribution Channel, and Region Forecast 2020-2031
Huntington’s Disease Treatment Market size was valued at US$ 579.6 million in 2024 and is expected to reach US$ 1,947.3 million by 2031, growing at a significant CAGR of 18.9% from 2025-2031. Moreover, in the USA, the Huntington’s Disease Treatment market size is projected to reach US$ 607.6 million by 2031. Demand for treatment of huntington's disease is led mainly by the increasing demand for therapies to treat chorea symptoms. best-selling medicines tetrabenazine, deutetrabenazine, and valbenazine are prescribed to treat symptoms, with robust demand for symptomatic and disease-modifying therapies. Hospital, retail, and internet pharmacy distribution provide increased access to these medications.
Market opportunities are significant against these constraints of regulatory issues, reimbursement concerns, and cost of production, particularly in Europe and North America, where the prevalence of HD is higher. Also, expansion in emphasis on homecare and ambulatory therapies with the government's facilitation are expanding access to treatment. Drug delivery technological advancements, such as handheld and green devices, are also making market growth due to their efficiency and sustainability during treatment. As it is continually ongoing, advances in disease-altering therapy also bring unique treatment and better patient care in a growing market that ensures sustained long-term growth.
Based on the treatment type:
The symptomatic treatment segment dominates the market, as it primarily addresses the management of chorea and other physical and cognitive symptoms. Drugs like tetrabenazine, deutetrabenazine, and valbenazine are widely used to alleviate motor dysfunction, providing symptomatic relief and improving quality of life for patients.
Based on the drug type:
The tetrabenazine segment dominates the market. Tetrabenazine is widely used to manage chorea, the most common motor symptom of huntington’s disease. Its ability to effectively reduce involuntary movements has made it a preferred treatment option, driving significant market demand, particularly for patients in homecare settings.
Based on the distribution channel:
Hospital Pharmacies dominate the market. These pharmacies are preferred due to their proximity to healthcare professionals who can monitor patient progress closely. Hospital pharmacies ensure a continuous supply of prescribed medications, including tetrabenazine, deutetrabenazine, and valbenazine, which are crucial for managing symptoms in an inpatient setting.
Study Period
2025-2031Base Year
2024CAGR
18.9%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
The market is primarily driven by the rising prevalence of HD, particularly in North America and Europe, where it affects approximately 30,000 people in the U.S. and up to 10 out of 100,000 people in Europe. As the patient population grows, the demand for effective treatments continues to rise. Advancements in disease-modifying therapies, such as gene therapies and neuroprotective drugs, offer the potential to slow or halt disease progression, fueling market growth. Symptomatic treatments like tetrabenazine, deutetrabenazine, and valbenazine, which help manage chorea, remain crucial in enhancing patients' quality of life. The increasing adoption of homecare solutions, where patients can self-administer treatments, is another key factor driving the market, as it reduces hospital stays. Biopharmaceutical innovations, including personalized medicines and biologics, are expanding treatment options.
In addition, government funding and research initiatives, especially from organizations like the NIH, are accelerating the development of new therapies. Improvements in genetic testing enable earlier diagnosis and better disease management. Regulatory approvals for new treatments, such as valbenazine, continue to strengthen market momentum, further contributing to the growth of the HD treatment market.
The market faces several significant restraints that hinder its growth. One of the primary challenges is the high cost of the treatments, particularly the new ones like the gene therapies and disease-modifying therapies. They are usually lengthy and costly and therefore out of reach for the majority of the patients, mostly in under-funded healthcare settings. Second, symptomatic therapy for HD patients is present, yet there is no treatment option for HD at present, and the lack of disease-modifying drugs that reverse the pathologic basis of the illness limits treatment and patient satisfaction. Regulatory barriers and prolonged approval windows for new treatments also delay market growth, as enormous clinical trials and safety assessments must happen before approval.
Moreover, delayed diagnosis due to insufficient knowledge of HD among healthcare professionals could result in interventions at a later point in the disease, reducing the effectiveness of available interventions. Ethical concerns over genetic testing and psychological effects could discourage some from seeking enrollment in diagnosis and treatment, hence restricting the number of patients. Finally, compliance on the part of patients with chronic treatment regimens is a factor as predictive nature of the disease and side effects due to therapy will dictate punctual application of regular therapy.
The market presents several key opportunities that can drive growth during the forecast period. Development of disease-modifying drugs, which can reverse or even stop the progression of the disease, and clinical research into gene and RNA therapies are starting to produce auspicious results. Also, the expanding trend of personalized medicine offers an opportunity to formulate treatments based on individual genetic patterns, potentially optimizing treatment impact and benefit to the patient. Furthermore, further research investments and cooperation among biotech firms, academia, and government agencies are driving HD treatment innovation towards the hopes of breakthrough treatments. Growing awareness of HD is also an opportunity, with rising diagnoses translating to better intervention and greater effectiveness of existing treatments.
Moreover, expanding access to treatment globally, focusing on the BRIC and other emerging economies, is a huge growth opportunity in the wake of unprecedented, untapped patient pools in Asian and Latin American markets. Besides that, the quick approval of new therapies, such as gene therapies, will assist in bringing innovative medicines to the market faster, accelerating the industry's growth at a quicker rate. The treatment of huntington's disease is going through some significant trends that are shaping its future development.
The market is experiencing several significant trends that are shaping its future growth. One key trend is the growing focus on gene therapy, with companies like Neurocrine Biosciences and Prilenia Therapeutics developing promising treatments targeting the genetic mutations responsible for HD. This approach is expected to bring more disease-modifying therapies to market. Additionally, there is a shift towards personalized medicine, where treatments are tailored to individual patients based on their genetic makeup and disease progression, improving treatment outcomes. Another trend is the increasing use of combination therapies, which combine symptomatic treatments with emerging therapies to better manage both motor and cognitive symptoms of HD.
Furthermore, advancements in biomarkers and diagnostic tools are enabling earlier detection of the disease, allowing for more effective interventions and better patient management. The expansion of treatment access to underserved regions, particularly in Asia and Latin America, is also contributing to market growth. Lastly, regulatory support for innovative therapies is accelerating the development and availability of new treatments, especially gene therapies, through fast-track approvals and breakthrough designations.
Report Benchmarks |
Details |
Report Study Period |
2025-2031 |
Market Size in 2024 |
US$ 579.6 million |
Market Size in 2031 |
US$ 1,947.3 million |
Market CAGR |
18.9% |
By Treatment Type |
|
By Drug Type |
|
By Distribution Channel |
|
By Region |
|
The market is poised for significant growth, driven by increasing disease prevalence and advancements in treatment options. North America dominates the market, accounting for a significant share due to the high HD prevalence, robust healthcare infrastructure, and ongoing drug approvals like Valbenazine. Europe follows closely, with increasing regulatory collaborations propelling market growth. However, the Asia Pacific region is expected to experience the fastest CAGR, attributed to rising disease awareness and improving healthcare access, especially in developing countries like China and India.
Key developments include the advancement of gene therapies, with AMT-130 (uniQure) currently in Phase 1/2 trials, showing potential for disease-modifying treatments. Symptomatic treatments, including tetrabenazine, deutetrabenazine, and valbenazine, continue to be widely used to manage chorea, the most common symptom. The market faces challenges from high treatment costs and regulatory hurdles but is supported by opportunities in personalized medicine and expanding market access, particularly in emerging regions. The continuous innovations in drug delivery and gene therapy hold the promise of transforming patient care.
Download Free Sample Report
The huntington’s disease treatment market size was valued at US$ 579.6 million in 2024 and is projected to grow at a CAGR of 18.9% from 2025-2031.
• Rising Prevalence and Awareness • Advancements in Disease-Modifying Therapies • Government Support and Funding
• Regulatory Support for Fast-Tracking Innovative Therapies • Development of Disease-Modifying Therapies • Growing Research Collaborations
The market reports cover the treatment type, drug type, distribution channel, and region segment.
Asia Pacific is the fastest-growing region in the market.
1.Executive Summary |
2.Global Huntington’s Disease Treatment Market Introduction |
2.1.Global Huntington’s Disease Treatment Market - Taxonomy |
2.2.Global Huntington’s Disease Treatment Market - Definitions |
2.2.1.Treatment Type |
2.2.2.Drug Type |
2.2.3.Distribution Channel |
2.2.4.Region |
3.Global Huntington’s Disease Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Huntington’s Disease Treatment Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Huntington’s Disease Treatment Market By Treatment Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
5.1. Symptomatic Treatment |
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Disease Modifying Therapies |
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Huntington’s Disease Treatment Market By Drug Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
6.1. Tetrabenazine |
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Deutetrabenazine |
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Valbenazine |
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Huntington’s Disease Treatment Market By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Huntington’s Disease Treatment Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Huntington’s Disease Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
9.1. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Symptomatic Treatment |
9.1.2.Disease Modifying Therapies |
9.2. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Tetrabenazine |
9.2.2.Deutetrabenazine |
9.2.3.Valbenazine |
9.2.4.Others |
9.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Online Pharmacies |
9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Huntington’s Disease Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
10.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Symptomatic Treatment |
10.1.2.Disease Modifying Therapies |
10.2. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Tetrabenazine |
10.2.2.Deutetrabenazine |
10.2.3.Valbenazine |
10.2.4.Others |
10.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Online Pharmacies |
10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Huntington’s Disease Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
11.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Symptomatic Treatment |
11.1.2.Disease Modifying Therapies |
11.2. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Tetrabenazine |
11.2.2.Deutetrabenazine |
11.2.3.Valbenazine |
11.2.4.Others |
11.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Online Pharmacies |
11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Huntington’s Disease Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
12.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Symptomatic Treatment |
12.1.2.Disease Modifying Therapies |
12.2. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Tetrabenazine |
12.2.2.Deutetrabenazine |
12.2.3.Valbenazine |
12.2.4.Others |
12.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Online Pharmacies |
12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Huntington’s Disease Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
13.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Symptomatic Treatment |
13.1.2.Disease Modifying Therapies |
13.2. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Tetrabenazine |
13.2.2.Deutetrabenazine |
13.2.3.Valbenazine |
13.2.4.Others |
13.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Online Pharmacies |
13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Lupin |
14.2.2.Novartis AG |
14.2.3.H. Lundbeck A/S |
14.2.4.Prilenia Therapeutics |
14.2.5.Hikma Pharmaceuticals PLC |
14.2.6.Bausch Health Companies Inc. |
14.2.7.Neurocrine Biosciences, Inc. |
14.2.8.Dr. Reddy’s Laboratories Ltd. |
14.2.9.Teva Pharmaceutical Industries Ltd. |
14.2.10.Sun Pharmaceutical Industries, Inc. |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players